Study guide
Immunotherapy Toxicities and CRS ICANS Case Lab
OCN Oncology Certified Nurse Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: OCN Exam Orientation and Official Source Control
Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness
2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care
Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures
3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment
Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation
4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards
Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development
5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy
Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation
6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents
Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation
7 Chapter 7: Symptom Management and Supportive Care
Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination
8 Chapter 8: Oncologic Emergencies and Rapid Escalation
Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage
9 Chapter 9: Psychosocial Dimensions of Oncology Care
Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals
10 Chapter 10: Mixed OCN Case Labs
New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab
11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness
Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning
Immunotherapy Toxicities and CRS ICANS Case Lab
Key Takeaways Explain This Topic AI
Immune checkpoint inhibitors cause immune-related adverse events (irAEs) in any organ, during or months after therapy; first-line treatment is corticosteroids per provider order, not antibiotics or loperamide.
Grade 2+ checkpoint-inhibitor diarrhea (4-6 stools/day above baseline) warrants holding the drug, stool studies, and steroid evaluation; never give routine loperamide for suspected immune colitis.
ASTCT consensus grades CRS by the worst of fever (>=38 C), hypotension, and hypoxia; Grade 1 is fever alone.
ICANS is graded with the 10-point ICE score plus consciousness, seizures, motor findings, and cerebral edema; tocilizumab treats CRS but NOT ICANS and may worsen it.
Teach delayed-toxicity reporting and wallet cards; patients must tell every clinician, including the ED, about immunotherapy.
Last updated: June 2026
- Case Lab: Immunotherapy Toxicities, CRS, and ICANS
- Case Snapshot
A 67-year-old on pembrolizumab for metastatic lung cancer calls with six watery stools per day, cramping, and fatigue. In the same unit, a patient is day 3 after CAR T-cell therapy with fever 39.2 C, a new oxygen requirement, and mild confusion. Both involve immune-based therapy, but nursing priorities differ by syndrome and severity.
Immune Checkpoint Inhibitor Toxicities (irAEs)
Checkpoint inhibitors (anti-PD-1 such as pembrolizumab/nivolumab, anti-PD-L1, anti-CTLA-4 such as ipilimumab) unleash T-cell activity against tumor and against normal tissue. Immune-related adverse events can hit skin, colon, liver, lung, endocrine organs, kidney, heart, nerves, eyes, or joints, and may appear weeks to months after the last dose, including after a patient lands in an ED that does not know the history. First-line treatment for grade 2+ irAEs is corticosteroids per oncology order, not loperamide or empiric antibiotics.
Symptom Pattern Possible irAE Nursing Priority
Diarrhea/abdominal pain/blood/fever Immune-mediated colitis Grade stools above baseline, assess hydration, notify provider
- Cough, dyspnea, hypoxia Pneumonitis Urgent assessment and escalation; check SpO2
- Headache, profound fatigue, hypotension Hypophysitis / adrenal crisis Labs per order, urgent provider contact
- Jaundice, dark urine, RUQ pain Immune hepatitis Stop casual acetaminophen advice, notify provider
- Chest pain, palpitations, syncope Myocarditis (high mortality) Emergency evaluation
The patient with six watery stools per day is at grade 2 colitis (4-6 stools/day above baseline). Do not advise routine loperamide and continued therapy; loperamide can mask worsening colitis. Assess stool count above baseline, hydration, fever, blood, abdominal pain, and intake, then notify the provider, who may hold the drug, order stool studies to exclude infection, and start corticosteroids; steroid-refractory colitis escalates to infliximab. RN scope is assessment, triage, education, and protocol care, not diagnosing colitis or prescribing steroids.
CRS Recognition and Grading
Cytokine release syndrome (CRS) follows CAR T-cell therapy and some bispecific antibodies. Fever is usually the first sign. The ASTCT consensus grades by the worst parameter among fever (>=38 C), hypotension, and hypoxia: Grade 1 is fever alone; higher grades add escalating hypotension and oxygen need. Know the product-specific monitoring window, fever protocol, and whether tocilizumab (anti-IL-6 receptor) and corticosteroids are available. For the day-3 patient with fever and new oxygen need, obtain vitals, SpO2, hemodynamics, mental status, IV access, and infection-workup orders, then notify the provider immediately.
Sepsis and CRS look alike and both demand urgent action; do not dismiss fever as expected.
ICANS Recognition
Immune effector cell-associated neurotoxicity syndrome (ICANS) includes confusion, word-finding difficulty, tremor, handwriting deterioration, decreased consciousness, seizure, cerebral edema, or motor weakness. It is graded with the 10-point ICE score (orientation, naming, following commands, writing, attention) plus level of consciousness, seizures, motor findings, and signs of raised intracranial pressure. A small change matters: a patient who cannot name the year, write a familiar sentence, or follow commands needs escalation.
Critically, tocilizumab treats CRS but does not treat ICANS and may worsen it because it does not cross the blood-brain barrier well; ICANS is managed with corticosteroids and supportive seizure precautions per protocol.
Patient Education and Documentation
Checkpoint-inhibitor patients must report promptly: new diarrhea, cough, dyspnea, rash, jaundice, severe fatigue, headache, vision changes, mood or cognition changes, chest pain, or decreased urine. They carry an immunotherapy wallet card , tell every clinician (including the ED), and avoid starting steroids, antidiarrheals, supplements, or antibiotics without oncology guidance. Cellular-therapy patients need fever and neurologic instructions, caregiver monitoring, a driving restriction (typically 8 weeks) , proximity-to-center requirements, and infection precautions.
Document baseline and current symptoms, therapy type and date, grading elements (ICE score, fever, SpO2, blood pressure), provider notification, orders, response, and education. Reassess often, because CRS and ICANS can worsen within hours.
Grading Logic and Exam Traps
The ASTCT consensus is graded by the single worst parameter , so a patient with only fever is Grade 1 even if other vitals are normal, while a patient needing high-flow oxygen and pressors is Grade 3-4 regardless of how mild the fever was. After a patient has received tocilizumab or steroids, fever is no longer required to grade subsequent CRS severity, because antipyretic effects mask it; grading then leans on hypotension and hypoxia.
The ICE score's ten points come from orientation (4), naming three objects (3), following a command (1), writing a sentence (1), and counting backward from 100 by tens (1); a drop in handwriting quality is an early, easily missed ICANS sign.
High-yield distinctions and traps:
Pseudoprogression with checkpoint inhibitors means a tumor can appear to enlarge before shrinking; teach patients not to assume failure from one scan, and do not stop therapy on imaging alone.
Treating immune colitis with empiric antibiotics instead of corticosteroids is a wrong answer; antibiotics are added only if infection (such as C. difficile) is suspected.
Giving acetaminophen to a febrile CAR T-cell patient before cultures can mask the picture and is a distractor; assess and escalate first.
The CAR T-cell driving restriction (typically 8 weeks) and caregiver proximity rules exist because ICANS can develop suddenly.
On mixed immunotherapy items, the safe answer recognizes severity, follows the cellular-therapy or irAE protocol, escalates early, avoids masking symptoms without direction, and never confuses the CRS drug (tocilizumab) with ICANS management (corticosteroids).